Nanobiotix (NASDAQ:NBTX) Trading 8.9% Higher – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares traded up 8.9% during mid-day trading on Wednesday . The company traded as high as $34.18 and last traded at $33.6150. 6,247 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 44,243 shares. The stock had previously closed at $30.87.

Key Stories Impacting Nanobiotix

Here are the key news stories impacting Nanobiotix this week:

• Positive Sentiment: Guggenheim raised its price target on NBTX from $26 to $36 and initiated/maintained a “Buy” rating — a supportive analyst upgrade that signals ~16% upside from the cited price and may attract fresh buying interest. Benzinga Coverage
• Positive Sentiment: HC Wainwright issued a bullish long-term EPS view, forecasting FY2030 EPS of $2.33 (well above consensus for current-year losses), which underscores expectations for meaningful recovery/value creation over the coming years. MarketBeat: HC Wainwright Estimates
• Neutral Sentiment: The Q4 2025 earnings call transcript is available for investors who want management detail on results, guidance and program timelines — useful for due diligence but not a single catalyst. Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed its FY2028 EPS estimate to $0.58 from $0.68 — a pullback in medium-term profitability expectations that can weigh on sentiment and be a source of profit-taking. MarketBeat: Estimate Revision
• Negative Sentiment: HC Wainwright slightly lowered its FY2026 EPS estimate to $1.05 from $1.06 — a modest downgrade but consistent with the theme of trimmed near-term forecasts. MarketBeat: Estimate Revision

Wall Street Analyst Weigh In

Several research firms have weighed in on NBTX. Guggenheim upped their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday. TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Nanobiotix has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Nanobiotix Trading Down 8.9%

The company has a 50-day moving average of $28.10 and a 200-day moving average of $23.25.

Nanobiotix (NASDAQ:NBTX) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The company had revenue of $3.42 million during the quarter. As a group, research analysts forecast that Nanobiotix S.A. – Sponsored ADR will post -1.18 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Optiver Holding B.V. purchased a new position in Nanobiotix during the third quarter worth about $101,000. Marshall Wace LLP purchased a new stake in Nanobiotix in the 4th quarter valued at about $220,000. Royal Bank of Canada lifted its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Nanobiotix during the 4th quarter worth approximately $390,000. 38.81% of the stock is owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.